The Latest Breaking News from EMA

A search firm is looking for Norman's replacement to lead LIV Golf and among its preliminary calls was a college conference commissioner, who wasn't interested.

Researchers found cases of the obesity drug putting patients at greater risk of suicidal ideation.

Rowe Racing's appeal against the result of the Nurburgring 24 Hour race has failed, ensuring Scherer Sport Phx drivers Christopher Mies, Dennis Marschall, Frank Stippler and Ricardo Feller remain victorious.

Campaigner welcomes investigation into drug after hundreds of suspected adverse reactions

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…

Lietz revealed that he at first "had no idea" about the significance of his pass on team-mate Klaus Bachler into Les Combes, which secured victory for the #91 Manthey EMA Porsche he shared with Yasser Shahin and Morris Schuring, as he had begun the final tour in third place.

A total of 20 drivers are competing in the DTM in 2024, representing nine teams and seven different manufacturers.

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Growing medical needs, surging demand for precision medicine, favorable regulatory climate, and rapid digital transformation would create promising growth opportunities for pharma companies. Hence, it could be wise to invest in top pharma stocks Johnson & Johnson (JNJ), Spero Therapeutics (SPRO), Ipsen (IPSEY), and Procaps Group (PROC) for solid gains.…